Sorry, you need to enable JavaScript to visit this website.

NYVEPRIA (pegfilgrastim-apgf) Indications and Usage

1 INDICATIONS AND USAGE

NYVEPRIA is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia [see Clinical Studies (14)].

Limitations of Use

NYVEPRIA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

What's New

No Current Announcements.

Contact Pfizer Medical

Search

Please enter your search term(s) for NYVEPRIA